HEMASURE FILING 510(K) BY YEAR-END FOR LEUKONET FILTER LEUKOCYTE REMOVAL SYSTEM; SEPRACOR SUBSIDIARY EXPECTS TO NET $15- $17 MIL. FROM INITIAL PUBLIC OFFERING
This article was originally published in The Gray Sheet
Executive Summary
HemaSure plans to file a 510(k) in the second half of 1994 for its lead product, the LeukoNet Filter for removing leukocytes from red blood cells and platelet concentrates, the Sepracor subsidiary notes in a March 10 registration statement with the Securities and Exchange Commission for an initial public offering.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.